The theory of FBDD believes that the active pockets of many drug targets are composed of multiple subactive cavities. The fragments of the active compound obtained by HTS often cannot bind well to the subactive cavities of the target protein. The optimization of the product often affects the entire molecule, and even changes the binding position to the target, leading to loss of activity. The FBDD method connects the fragments that specifically bind to each subactive cavity of the target protein with suitable linkers to assemble them into compounds with high activity. Therefore, drugs designed by the FBDD method often have the characteristics of high activity and high selectivity
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of...
Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the ac...
Fragment-based drug discovery (FBDD) is a powerful strategy for the identification of new bioactive ...
The aim of fragment-based drug design (FBDD) is to identify molecular fragments that bind to alterna...
In this review, a general introduction to fragment-based drug design and the underlying concepts is ...
The aim of fragment-based drug design (FBDD) is to identify molecular fragments that bind to alterna...
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical pro...
Fragment-based drug discovery (FBDD) is an important technology in drug discovery that seeks to iden...
A semi-exhaustive approach and a heuristic search algorithm use a fragment-based drug design (FBDD) ...
Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. ...
This book presents a company-based view of the recent progresses in fragment-based drug discovery (F...
Fragment-based screens test multiple low-molecular weight molecules for binding to a target. Fragmen...
Fragment-based drug discovery typically requires an interplay between screening methods, structural ...
Previously held under moratorium in Chemistry department (GSK) from 25/05/2016 until 18/06/2021.The ...
Previously held under moratorium in Chemistry department (GSK) from 2015 until 12th October 2017. Th...
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of...
Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the ac...
Fragment-based drug discovery (FBDD) is a powerful strategy for the identification of new bioactive ...
The aim of fragment-based drug design (FBDD) is to identify molecular fragments that bind to alterna...
In this review, a general introduction to fragment-based drug design and the underlying concepts is ...
The aim of fragment-based drug design (FBDD) is to identify molecular fragments that bind to alterna...
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical pro...
Fragment-based drug discovery (FBDD) is an important technology in drug discovery that seeks to iden...
A semi-exhaustive approach and a heuristic search algorithm use a fragment-based drug design (FBDD) ...
Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. ...
This book presents a company-based view of the recent progresses in fragment-based drug discovery (F...
Fragment-based screens test multiple low-molecular weight molecules for binding to a target. Fragmen...
Fragment-based drug discovery typically requires an interplay between screening methods, structural ...
Previously held under moratorium in Chemistry department (GSK) from 25/05/2016 until 18/06/2021.The ...
Previously held under moratorium in Chemistry department (GSK) from 2015 until 12th October 2017. Th...
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of...
Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the ac...
Fragment-based drug discovery (FBDD) is a powerful strategy for the identification of new bioactive ...